UPDATE: Northland Downgrades ResMed
In a note released Tuesday morning, Northland Securities downgraded ResMed (NYSE: RMD) from Market perform to Underperform and maintained its $40 price target.
In the note, Northland analyst cited "numerous forces" in the CPAP space that will squeeze margins and the top-line overtime. Furthermore, the analysts noted that ResMed's model is "highly sensitive" to operating margins and believe that consensus estimates are "unrealistic."
Shares of ResMed are down a little over one percent at $49.44 in Tuesday's trading.
Latest Ratings for RMD
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 2022 | Citigroup | Upgrades | Neutral | Buy |
| Jan 2022 | RBC Capital | Upgrades | Underperform | Sector Perform |
| Jan 2022 | JP Morgan | Upgrades | Neutral | Overweight |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Northland SecuritiesDowngrades Price Target Analyst Ratings
